EPCAM is altered in 0.6% of malignant solid tumor patients [3].

EPCAM is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain EPCAM status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

EPCAM is altered in 1.79% of adenocarcinoma of the gastroesophageal junction patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 1.48% of melanoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.89% of bladder carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 1.1% of malignant uterine neoplasm patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.68% of hepatocellular carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.75% of central nervous system neoplasm patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

EPCAM is altered in 0.79% of ovarian carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.49% of gallbladder carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.6% of colorectal carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.44% of head and neck carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.56% of non-small cell lung carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.53% of lung carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.47% of breast carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.33% of cervical carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.26% of pancreatic carcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.81% of lymphoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

EPCAM is altered in 0.33% of gastric adenocarcinoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is altered in 0.43% of soft tissue sarcoma patients [3].

EPCAM is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPCAM is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].